(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.

$600,621R01FY2020CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Theresa A Guisecontact Andrew R Marks Paul Richard Territo

Linked publications, trials & patents

Paper 37756377 Paper 35412613 Paper 34718221 Paper 34489173 Paper 30625309 Paper 29593014 Paper 28499500

View original record on NIH RePORTER →